Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

[up] Up a level
Number of items: 38.

Glaviano, Antonino, Wander, Seth A., Baird, Richard D., Yap, Kenneth C.-H., Lam, Hiu Yan, Toi, Masakazu, Carbone, Daniela, Geoerger, Birgit, Serra, Violeta, Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Ngeow, Joanne, Toska, Eneda, Stebbing, Justin, Crasta, Karen, Finn, Richard S., Diana, Patrizia, Vuina, Karla, de Bruin, Robertus A.M., Surana, Uttam, Bardia, Aditya and Kumar, Alan Prem 2024. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resistance Updates 76 , 101103. 10.1016/j.drup.2024.101103
file

Fizazi, Karim, Bernard-Tessier, Alice, Roubaud, Guilhem, Utriainen, Tapio, Barthélémy, Philippe, Fléchon, Aude, van der Voet, Johannes, Gravis, Gwenaëlle, Ratta, Raffaele, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Parikh, Omi, Tanner, Minna, Antonarakis, Emmanuel S., Baldini, Capucine, Peters, Niamh, Garratt, Chris, Ikonen, Tarja, Pohjanjousi, Pasi, Joensuu, Heikki and Cook, Natalie 2024. Targeted inhibition of CYP11A1 in castration-resistant prostate cancer. NEJM Evidence 3 (1) 10.1056/EVIDoa2300171
file

Jones, Robert Hugh ORCID: https://orcid.org/0000-0003-3576-9496, Fizazi, Karim, James, Nicholas D., Tammela, Teuvo L., Matsubara, Nobuaki, Priou, Frank, Beuzeboc, Philippe, Lesimple, Thierry, Bono, Petri, Kataja, Vesa, Garcia, Jorge A., Protheroe, Andrew, Shore, Neal, Aspegren, John, Joensuu, Heikki, Kuss, Iris, Fiala-Buskies, Sabine and Vjaters, Egils 2023. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 10.1038/s41391-023-00740-9
file

Macaulay, Valentine M., Lord, Simon, Hussain, Syed, Maroto, José Pablo, Jones, Robert Hugh ORCID: https://orcid.org/0000-0003-3576-9496, Climent, Miguel Ángel, Cook, Natalie, Lin, Chia-Chi, Wang, Shian-Shiang, Bianchini, Diletta, Bailey, Mark, Schlieker, Laura, Bogenrieder, Thomas and de Bono, Johann 2023. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British Journal of Cancer 129 , pp. 965-973. 10.1038/s41416-023-02380-1
file

Beresford, Mark, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia ORCID: https://orcid.org/0000-0001-6483-2015, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1 (1) , 13. 10.1038/s44276-023-00016-8
filefile

Glaviano, Antonino, Foo, Aaron S. C., Lam, Hiu Y., Yap, Kenneth C. H., Jacot, William, Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Eng, Huiyan, Nair, Madhumathy G., Makvandi, Pooyan, Geoerger, Birgit, Kulke, Matthew H., Baird, Richard D., Prabhu, Jyothi S., Carbone, Daniela, Pecoraro, Camilla, Teh, Daniel B. L., Sethi, Gautam, Cavalieri, Vincenzo, Lin, Kevin H., Javidi-Sharifi, Nathalie R., Toska, Eneda, Davids, Matthew S., Brown, Jennifer R., Diana, Patrizia, Stebbing, Justin, Fruman, David A. and Kumar, Alan P. 2023. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer 22 , 138. 10.1186/s12943-023-01827-6
file

Arana Echarri, Ainhoa, Struszczak, Lauren, Beresford, Mark, Campbell, John P., Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Thompson, Dylan and Turner, James E. 2023. Immune cell status, cardiorespiratory fitness and body composition among breast cancer survivors and healthy women: a cross sectional study. Frontiers in Physiology 14 , 1107070. 10.3389/fphys.2023.1107070
file

Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M. and Banerji, Udai 2023. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer 10.1038/s41416-023-02279-x
file

Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Plummer, Ruth, Moreno, Victor, Carter, Louise, Roda, Desamparados, Garralda, Elena, Kristeleit, Rebecca, Sarker, Debashis, Arkenau, Tobias, Roxburgh, Patricia, Walter, Harriet S., Blagden, Sarah, Anthoney, Alan, Klencke, Barbara J., Kowalski, Mark M. and Banerji, Udai 2023. A Phase I/II trial of Oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clinical Cancer Research 29 (2) , pp. 331-340. 10.1158/1078-0432.CCR-22-2074
file

Saad, Fred, Thiery-Vuillemin, Antoine, Wiechno, Pawel, Alekseev, Boris, Sala, Nuria, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Kocak, Ivo, Chiuri, Vincenzo Emanuele, Jassem, Jacek, Fléchon, Aude, Redfern, Charles, Kang, Jinyu, Burgents, Joseph, Gresty, Christopher, Degboe, Arnold and Clarke, Noel W 2022. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology 23 (10) , pp. 1297-1307. 10.1016/S1470-2045(22)00498-3
file

Banerjee, Susana, Michalarea, Vasiliki, Ang, Joo Ern, Ingles Garces, Alvaro, Biondo, Andrea, Funingana, Ionut-Gabriel, Little, Martin, Ruddle, Ruth, Raynaud, Florence, Riisnaes, Ruth, Gurel, Bora, Chua, Sue, Tunariu, Nina, Porter, Joanna C., Prout, Toby, Parmar, Mona, Zachariou, Anna, Turner, Alison, Jenkins, Ben, McIntosh, Stuart, Ainscow, Edward, Minchom, Anna, Lopez, Juanita, de Bono, Johann, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Hall, Emma, Cook, Natalie, Basu, Bristi and Banerji, Udai 2022. A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clinical Cancer Research 22 , 1268. 10.1158/1078-0432.CCR-22-1268

Howell, Sacha J., Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Carucci, Margherita, Ingarfield, Kate, Butler, Rachel, Morgan, Sian, Meissner, Magdalena, Bale, Catherine, Bezecny, Pavel, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, De Bruin, Elza C., Schiavon, Gaia, Foxley, Andrew and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2022. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology 23 (7) , pp. 851-864. 10.1016/s1470-2045(22)00284-4
file

Seligmann, Jenny F., Fisher, David J., Brown, Louise C., Adams, Richard A. ORCID: https://orcid.org/0000-0003-3915-7243, Graham, Janet, Quirke, Philip, Richman, Susan D., Butler, Rachel, Domingo, Enric, Blake, Andrew, Yates, Emma, Braun, Michael, Collinson, Fiona, Jones, Rob ORCID: https://orcid.org/0000-0003-3576-9496, Brown, Ewan, de Winton, Emma, Humphrey, Timothy C., Parmar, Mahesh, Kaplan, Richard, Wilson, Richard H., Seymour, Matthew and Maughan, Timothy S. 2021. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. Journal of Clinical Oncology 39 (33) , pp. 3705-3715. 10.1200/JCO.21.01435
file

Arana Echarri, Ainhoa, Beresford, Mark, Campbell, John P., Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Butler, Rachel, Gollob, Kenneth J., Brum, Patricia C., Thompson, Dylan and Turner, James E. 2021. A phenomic perspective on factors influencing breast cancer treatment: integrating aging and lifestyle in blood and tissue biomarker profiling. Frontiers in Immunology 11 , 616188. 10.3389/fimmu.2020.616188
file

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew and Howell, Sacha J. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21 (3) , pp. 345-347. 10.1016/S1470-2045(19)30817-4
file

Hong, David S., Concin, Nicole, Vergote, Ignace, de Bono, Johann S., Slomovitz, Brian M, Drew, Yvette, Arkenau, Hendrik-Tobias, Machiels, Jean-Pascal, Spicer, James, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Forster, Martin, Cornez, Nathalie, Gennigens, Christine, Johnson, Melissa L, Thistlethwaite, Fiona C, Rangwala, Reshma A, Ghatta, Srinivas, Windfeld, Kristian, Harris, Jeffrey R, Lassen, Ulrik Niels and Coleman, Robert L. 2020. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clinical Cancer Research 26 (6) , pp. 1220-1228. 10.1158/1078-0432.CCR-19-2962
file

Peltola, Katriina J., Bono, Petri, Jones, Robert Hugh ORCID: https://orcid.org/0000-0003-3576-9496, Vjaters, Egils, Nykänen, Pirjo, Vuorela, Annamari, Oksala, Riikka, Pohjanjousi, Pasi, Mustonen, Mika V.J., Fizazi, Karim and Massard, Christopher 2020. ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer. European Urology Focus 6 (1) , pp. 63-70. 10.1016/j.euf.2018.08.022
file

de Bono, Johann S., Concin, Nicole, Hong, David S., Thistlethwaite, Fiona C., Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh ORCID: https://orcid.org/0000-0003-3576-9496, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M., Spicer, James F., Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A. and Lassen, Ulrik 2019. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncology 20 (3) , pp. 383-393. 10.1016/S1470-2045(18)30859-3
file

Basu, B., Krebs, M. G., Sundar, R., Wilson, R. H., Spicer, J., Jones, R. ORCID: https://orcid.org/0000-0003-3576-9496, Brada, M., Talbot, D. C., Steele, N., Ingles Garces, A. H., Brugger, W., Harrington, E. A., Evans, J., Hall, E., Tovey, H., de Oliveira, F. M., Carreira, S., Swales, K., Ruddle, R., Raynaud, F. I., Purchase, B., Dawes, J. C., Parmar, M., Turner, A. J., Tunariu, N., Banerjee, S., de Bono, J. S. and Banerji, U. 2018. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology 29 (9) , pp. 1918-1925. 10.1093/annonc/mdy245
file

Clarke, Noel, Wiechno, Pawel, Alekseev, Boris, Sala, Nuria, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Kocak, Ivo, Chiuri, Vincenzo Emanuele, Jassem, Jacek, Fléchon, Aude, Redfern, Charles, Goessl, Carsten, Burgents, Joseph, Kozarski, Robert, Hodgson, Darren, Learoyd, Maria and Saad, Fred 2018. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology 19 (7) , pp. 975-986. 10.1016/S1470-2045(18)30365-6
file

Garcia Martin, Isabel, Janssen, A.B., Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Grimstead, Julia W., Penketh, Richard J. A., Baird, Duncan M. ORCID: https://orcid.org/0000-0001-8408-5467 and John, Rosalind M. ORCID: https://orcid.org/0000-0002-3827-7617 2017. Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis. Placenta 59 , pp. 61-68. 10.1016/j.placenta.2017.09.007
file

Scurr, Martin ORCID: https://orcid.org/0000-0002-4120-0688, Pembroke, Tom ORCID: https://orcid.org/0000-0002-2600-2034, Bloom, Anja, Roberts, David, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Brewster, Alison, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Wright, Melissa ORCID: https://orcid.org/0000-0002-1011-4795, Hills, Robert ORCID: https://orcid.org/0000-0003-0166-0062, Gallimore, Awen ORCID: https://orcid.org/0000-0001-6675-7004 and Godkin, Andrew ORCID: https://orcid.org/0000-0002-1910-7567 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3 (10) , e172579. 10.1001/jamaoncol.2017.2579
file

Scurr, Martin J ORCID: https://orcid.org/0000-0002-4120-0688, Pembroke, Tom, Bloom, Anja, Roberts, David J, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard A ORCID: https://orcid.org/0000-0003-3915-7243, Brewster, Alison E, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Hills, Robert ORCID: https://orcid.org/0000-0003-0166-0062, Gallimore, Awen ORCID: https://orcid.org/0000-0001-6675-7004 and Godkin, Andrew ORCID: https://orcid.org/0000-0002-1910-7567 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research , clincanres.0895.2017. 10.1158/1078-0432.CCR-17-0895
file

Scurr, Martin ORCID: https://orcid.org/0000-0002-4120-0688, Pembroke, Tom, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Blount, Daniel, Brewster, Alison, Gwynne, Sarah, Harrop, Richard, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Hills, Robert ORCID: https://orcid.org/0000-0003-0166-0062, Gallimore, Awen ORCID: https://orcid.org/0000-0001-6675-7004 and Godkin, Andrew ORCID: https://orcid.org/0000-0002-1910-7567 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial. Journal of Clinical Oncology 35 (7) , p. 154. 10.1200/JCO.2017.35.7_suppl.154
file

Reza, Mariana, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Aspegren, John, Massard, Christophe, Mattila, Leena, Mustonen, Mika, Wollmer, Per, Trägårdh, Elin, Bondesson, Eva, Edenbrandt, Lars, Fizazi, Karim and Bjartell, Anders 2016. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus 2 (5) , pp. 547-552. 10.1016/j.euf.2016.01.005
file

Fizazi, Karim, Massard, Christophe, Bono, Petri, Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Kataja, Vesa, James, Nicholas, Garcia, Jorge A., Protheroe, Andrew, Tammela, Teuvo L., Elliott, Tony, Mattila, Leena, Aspegren, John, Vuorela, Annamari, Langmuir, Peter and Mustonen, Mika 2014. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology 15 (9) , pp. 975-985. 10.1016/S1470-2045(14)70240-2
file

Greenow, K. R., Clarke, A. R. ORCID: https://orcid.org/0000-0002-4281-426X, Williams, G. T. ORCID: https://orcid.org/0000-0003-3768-9940 and Jones, R. ORCID: https://orcid.org/0000-0003-3576-9496 2014. Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency. Oncogene 33 , pp. 4089-4096. 10.1038/onc.2013.371

Greenow, Kirsty Rhian, Clarke, Alan Richard ORCID: https://orcid.org/0000-0002-4281-426X and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28 (11) , pp. 1443-1453. 10.1038/onc.2008.482

Robinson, H. M. R., Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. A. F. 2006. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25 (39) , pp. 5359-5369. 10.1038/sj.onc.1209532

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Reubi, Jean-Claude, Millan, David and Vasey, Paul 2004. Octreotide: an active agent in epithelial ovarian carcinoma? The Lancet Oncology 5 (4) , pp. 251-253. 10.1016/S1470-2045(04)01430-5

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 and Vasey, P. A. 2003. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer 39 (2) , pp. 147-156. 10.1016/S0959-8049(02)00612-3

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Ryan, Mary and Friedlander, Michael 2003. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology 89 (1) , pp. 112-115. 10.1016/S0090-8258(03)00066-0

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Goldstein, David, Kurtovic, Jelica, Keogh, Gregory and Riordan, Stephen M. 2003. Compression of liver parenchyma by a malignant hepatic cyst a previously unreported manifestation of metastatic gastric cancer [Letter]. The American Journal of Gastroenterology 98 (5) , pp. 1211-1213. 10.1016/S0002-9270(03)00170-9

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 and Vasey, Paul A 2003. Part II: Testicular cancer - management of advanced disease. The Lancet Oncology 4 (12) , pp. 738-747. 10.1016/S1470-2045(03)01279-8

Twelves, Chris and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy 2 (9) , pp. 1495-1505. 10.1517/14656566.2.9.1495

Millar, J. B., McGowan, C. H., Lenaers, G., Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496 and Russell, P. 1990. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. Embo Journal 10 (13) , pp. 5610-5621.

Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496 and Jones, N. C. 1989. Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 86 (7) , pp. 2176-2180.

Jones, Robert ORCID: https://orcid.org/0000-0003-3576-9496, Moreno, Sergio, Nurse, Paul and Jones, Nicholas C. 1988. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53 (4) , pp. 659-667. 10.1016/0092-8674(88)90581-8

This list was generated on Mon Nov 18 10:06:26 2024 GMT.


Maintained by Cardiff University Information Services